<DOC>
	<DOCNO>NCT01436864</DOCNO>
	<brief_summary>This study design prove confirm efficacy safety multiple injection human recombinant vascular endothelial growth factor receptor-Fc fusion protein ( KH902 ) patient choroidal neovascularization due neovascular age-related macular degeneration compare intravitreal injection KH902 sham-injections .</brief_summary>
	<brief_title>A Randomized , Double-masked , Multicenter , Sham-controlled , Safety Efficacy Study KH902 Patients With Wet AMD</brief_title>
	<detailed_description>AMD lead cause severe vision loss people age 65 United States western country . A quantity document indicate neovascularization promote VEGF main cause visual acuity decline . Patients starve new drug notably improve VA less administration frequency lower treatment cost . The new drug Recombinant Human VEGF Receptor-Fc Fusion Protein ( KH902 ) gene fusion protein . The pre-clinical research phase II study show KH902 well-tolerated , safe , effective inhibiting growth , migration , pullulation vascular endothelial cell neovascularization induce VEGF . This study design prove confirm efficacy safety multiple injection KH902 patient choroidal neovascularization due neovascular age-related macular degeneration compare intravitreal injection KH902 sham-injections .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<criteria>Signed Informed Consent Form ; Age ≥ 50 year either gender ; Total lesion size ≤ 30 mm2 study eye ; BCVA score study eye 73 19 letter ; Clear ocular medium adequate pupil dilation permit good quality fundus photographic imaging . BCVA score fellow eye ≥ 19 letter . Current previous nonexudative AMD disease affect inspection measurement macular central visual acuity ; Subretinal hemorrhage area≥ 50 % total lesion size ; Scar fibrosis area study eye ≥ 50 % total lesion size ; central foveal scar、fibrosis atrophy macular study eye ; Presence retinal pigment epithelial tear , retinal macular tractional , macular epiretinal membrane , diagnose polypoidal choroidal vasculopathy study eye ; Previous antiVEGF drug treatment study eye within six month precede screening ; antiVEGF treatment fellow eye within three month screen ; Previous intraocular periocular operation , exclude operation eyelid without hamper intravitreal injection study eye ; Previous ophthalmologic operation study eye ; Current active inflammation infection either eye ; Uncontrolled previous current glaucoma either eye , previous glaucoma filter operation study eye ; Current systemic administration may lead toxicity crystalline lens ; History allergy current allergic response ; History surgery within one month precede enrollment ; Infectious disease need systemic administration ; Systemic autoimmune disease ; Any uncontrolled clinical disorder ; Patients childbearing potential adopt adequate contraception method ; Pregnant nursing woman ; Patients exclude opinion investigator ;</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Recombinant Human VEGF Receptor-Fc Fusion Protein ( KH902</keyword>
	<keyword>)</keyword>
	<keyword>age-related macular degeneration ( AMD )</keyword>
	<keyword>choroidal neovascularization ( CNV )</keyword>
	<keyword>intravitreal injection</keyword>
	<keyword>best correct visual acuity ( BCVA )</keyword>
	<keyword>central retinal thickness</keyword>
</DOC>